FibroGen to Report Second Quarter Financial Results on Monday, August 7, 2017
July 31, 2017 19:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 31, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the second quarter...
About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
June 13, 2017 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate...
European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor Technology
June 05, 2017 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today that a FibroGen European patent relating to the therapeutic...
FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock
April 06, 2017 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 06, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that the company has priced an underwritten follow-on...
FibroGen’s Roxadustat (FG-4592) Meets Primary Endpoints in Two Phase 3 Anemia Studies in China
January 30, 2017 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Jan. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update
November 08, 2016 16:03 ET
|
FibroGen, Inc.
– Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD – – Conference Call and Webcast to be Held Today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific...
FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016
November 01, 2016 17:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
August 02, 2016 20:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Announces Receipt of $62 Million License Payment from AstraZeneca
July 08, 2016 04:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, July 08, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, announced today that it has received a scheduled $62 million...
FibroGen to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
June 06, 2016 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), announced that Chief Executive Officer, Thomas B. Neff, will be presenting at the Goldman Sachs 37th Annual Global...